利妥昔单抗对弥漫性大B细胞淋巴瘤成年患者中枢神经系统受累情况的影响
Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab.
作者信息
Cao Bing, Zhou Xiaoyan, Ji Dongmei, Cao Junning, Guo Ye, Zhang Qunling, Wu Xianghua, Li Junmin, Wang Jianmin, Chen Fangyuan, Wang Chun, Zou Shanhua, Hong Xiaonan
机构信息
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
出版信息
Oncol Lett. 2012 Sep;4(3):541-545. doi: 10.3892/ol.2012.755. Epub 2012 Jun 13.
Abstract
CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy, in combination with rituximab (R-CHOP-like), improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We aimed to investigate the impact of rituximab on central nervous system (CNS) disease in adult patients. We studied 315 patients (aged 18-60 years old) from six hospitals between July 2003 and May 2008. All patients received CHOP-like (n=165) or R-CHOP-like (n=150) regimen every 3 weeks. With a median follow-up of 3.69 years, 10 patients (3.17%) developed CNS disease. The cumulative risk of CNS occurrence was not significantly different between the two treatment groups (P=0.871). We conclude that the addition of rituximab did not reduce the risk of CNS disease in adult patients with DLBCL.
摘要
环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）样化疗联合利妥昔单抗（R-CHOP样）可改善弥漫性大B细胞淋巴瘤（DLBCL）患者的预后。我们旨在研究利妥昔单抗对成年患者中枢神经系统（CNS）疾病的影响。我们研究了2003年7月至2008年5月期间来自六家医院的315例患者（年龄在18至60岁之间）。所有患者每3周接受CHOP样（n = 165）或R-CHOP样（n = 150）方案治疗。中位随访3.69年，10例患者（3.17%）发生CNS疾病。两个治疗组之间CNS发生的累积风险无显著差异（P = 0.871）。我们得出结论，在成年DLBCL患者中添加利妥昔单抗并不能降低CNS疾病的风险。
相似文献
1
Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab.利妥昔单抗对弥漫性大B细胞淋巴瘤成年患者中枢神经系统受累情况的影响
Oncol Lett. 2012 Sep;4(3):541-545. doi: 10.3892/ol.2012.755. Epub 2012 Jun 13.
2
New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.弥漫性大B细胞淋巴瘤患者中枢神经系统复发的新危险因素及新趋势：一项回顾性研究
Chin J Cancer. 2016 Sep 13;35(1):87. doi: 10.1186/s40880-016-0150-y.
3
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.弥漫性大 B 细胞淋巴瘤患者中枢神经系统复发的发生率和危险因素：利妥昔单抗联合 CHOP 化疗的影响。
Ann Oncol. 2010 May;21(5):1046-52. doi: 10.1093/annonc/mdp432. Epub 2009 Oct 27.
4
Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.弥漫性大B细胞淋巴瘤累及睾丸：利妥昔单抗时代的预后及中枢神经系统复发风险
Br J Haematol. 2017 Jan;176(2):210-221. doi: 10.1111/bjh.14392. Epub 2016 Oct 14.
5
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.利妥昔单抗联合 CHOP 化疗治疗中国弥漫性大 B 细胞淋巴瘤：上海淋巴瘤研究组 437 例 10 年回顾性随访分析。
Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.
6
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
7
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.CNS 国际预后指数：R-CHOP 治疗弥漫性大 B 细胞淋巴瘤患者 CNS 复发的风险模型。
J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.
8
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP方案）用于治疗早期胃弥漫性大B细胞淋巴瘤。
Ann Oncol. 2004 Jul;15(7):1086-90. doi: 10.1093/annonc/mdh261.
9
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
10
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.伊布替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗初治 CD20 阳性 B 细胞非霍奇金淋巴瘤患者：一项非随机、1b 期研究。
Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.
引用本文的文献
1
Rare case of primary pleural lymphoma presenting with pleural effusion.原发性胸膜淋巴瘤伴胸腔积液的罕见病例。
Thorac Cancer. 2016 Jan;7(1):145-50. doi: 10.1111/1759-7714.12256. Epub 2015 Mar 26.
本文引用的文献
1
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.中枢神经系统（CNS）复发弥漫性大 B 细胞淋巴瘤（DLBCL）：利妥昔单抗治疗前后。
Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13.
2
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.静脉注射甲氨蝶呤作为中枢神经系统 (CNS) 预防措施，与高危弥漫性大 B 细胞淋巴瘤患者的 CNS 复发风险低相关。
Cancer. 2010 Sep 15;116(18):4283-90. doi: 10.1002/cncr.25278.
3
Central nervous system involvement in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的中枢神经系统累及。
Eur J Haematol. 2010 Jul;85(1):6-10. doi: 10.1111/j.1600-0609.2010.01438.x. Epub 2010 Mar 3.
4
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.弥漫性大 B 细胞淋巴瘤患者中枢神经系统复发的发生率和危险因素：利妥昔单抗联合 CHOP 化疗的影响。
Ann Oncol. 2010 May;21(5):1046-52. doi: 10.1093/annonc/mdp432. Epub 2009 Oct 27.
5
Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience.中枢神经系统复发的弥漫性大B细胞淋巴瘤：基于单中心经验的回顾性分析的预后及危险因素
Int J Hematol. 2009 Jun;89(5):577-83. doi: 10.1007/s12185-009-0289-2. Epub 2009 Apr 9.
6
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).采用含或不含利妥昔单抗的现代化疗方案（CHOP-14）治疗的侵袭性淋巴瘤老年患者的中枢神经系统事件：德国高级别非霍奇金淋巴瘤研究组（DSHNHL）RICOVER-60试验中患者的分析
Blood. 2009 Apr 23;113(17):3896-902. doi: 10.1182/blood-2008-10-182253. Epub 2009 Jan 14.
7
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.侵袭性非霍奇金淋巴瘤患者中枢神经系统复发的自然史：西南肿瘤学组（SWOG 8516）的20年随访分析
J Clin Oncol. 2009 Jan 1;27(1):114-9. doi: 10.1200/JCO.2008.16.8021. Epub 2008 Dec 1.
8
Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.侵袭性B细胞淋巴瘤继发中枢神经系统受累经全身大剂量化疗联合鞘内注射利妥昔单抗治疗后的持续缓解及长期生存
Leuk Lymphoma. 2008 Oct;49(10):2018-21. doi: 10.1080/10428190802311375.
9
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).老年侵袭性CD20+B细胞淋巴瘤患者接受每两周一次的CHOP-14方案化疗6周期与8周期并联合或不联合利妥昔单抗的疗效比较：一项随机对照试验（RICOVER-60）
Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.
10
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.利妥昔单抗脑室内给药治疗复发性中枢神经系统和眼内淋巴瘤的I期研究。
J Clin Oncol. 2007 Apr 10;25(11):1350-6. doi: 10.1200/JCO.2006.09.7311. Epub 2007 Feb 20.
Zotero 插件